Your browser doesn't support javascript.
loading
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Kim, Seung Tae; Smith, Simon A; Mortimer, Peter; Loembé, Arsene-Bienvenu; Cho, Heejin; Kim, Kyoung-Mee; Smith, Claire; Willis, Sophie; Irurzun-Arana, Itziar; Berges, Alienor; Hong, Jung Yong; Park, Se Hoon; Park, Joon Oh; Park, Young Suk; Lim, Ho Yeong; Kang, Won Ki; Kozarewa, Iwanka; Pierce, Andrew J; Dean, Emma; Lee, Jeeyun.
Afiliação
  • Kim ST; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Smith SA; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Mortimer P; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Loembé AB; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Cho H; Innovative Therapeutic Research Center, Precision Medicine Research Institute, Samsung Medical Center, Seoul, Korea.
  • Kim KM; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Smith C; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Willis S; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Irurzun-Arana I; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Berges A; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Hong JY; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Park SH; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Park JO; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Park YS; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Lim HY; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Kang WK; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Kozarewa I; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Pierce AJ; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Dean E; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Lee J; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea. jyunlee@skku.edu.
Clin Cancer Res ; 27(17): 4700-4709, 2021 09 01.
Article em En | MEDLINE | ID: mdl-33975862
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Pirimidinas / Sulfonamidas / Morfolinas / Paclitaxel / Indóis / Neoplasias / Antineoplásicos Fitogênicos Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Pirimidinas / Sulfonamidas / Morfolinas / Paclitaxel / Indóis / Neoplasias / Antineoplásicos Fitogênicos Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article